Eurasian Journal of Analytical Chemistry
ISSN: 1306-3057 OPEN ACCESS 2024 19 (1): 529-535

"Impact of post-COVID-19 pandemic on Asthmatic Patients: A Comprehensive Review."

Shruti Patel[1*], Ms. Sonika Rathi[1], Dr. Pragnesh Patani[2]

[1*]Khyati College of Pharmacy, Palodia, Ahmedabad
[2]Assistant Professor, Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad

[*]**Corresponding Author:** Shruti Patel
Email: sp9773283@gmail.com

ABSTRACT:
Since its worldwide attack in 2019, Coronavirus has impacted a few parts of patients' lives and represented a critical effect on the medical services framework. Patients with asthma were once assumed to be at a higher risk and severity of SARS-CoV-2 infection. However, emerging research shows that asthma endotypes/phenotypes and comorbidities increase risk stratification in this group. The emergence of additional variations of concerns such as Omicron BA.2, BA.4, and BA.5, as well as the global distribution of COVID-19 vaccinations, have altered the clinical picture of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) can produce severe and diverse illness but has a reduced fatality rate. Long-term COVID-19 symptoms may be caused by disruptions in T cell, B cell, and mast cell immunity, as well as autoantibodies and metabolic reprogramming. Moreover, there is little evidence to support early worries over a possible higher risk of unfavorable outcomes while using asthma medications such biologics and inhaled corticosteroids. Furthermore, ICS has been hypothesized to provide some protection against SARS-CoV-2 infection and the development of severe illness by decreasing the expression of angiotensin converting enzyme-2 and transmembrane protease serine in the lung. As discoveries propose that Th2-high irritation might decrease the gamble of SARS-Cov-2 contamination and illness seriousness as opposed to expanded risk in patients with Th2-low asthma. However, this article has overview about active cases, lifestyle, management and effect of COVID 19 on asthma.

KEYWORDS: COVID-19, Asthma, Phenotype, Inhaled corticosteroid, Polymorphism

1. INTRODUCTION:

SARS-CoV-2 contamination changed a few parts of living souls and has turned into a long-lasting piece of our day to day reality. Following the principal wild rushes of Coronavirus ending the existences of numerous patients in mid-2020, less destructive SARS-CoV-2 subtypes including the omicron variations, have advanced causing milder side effects with a general recuperation inside the space of days to weeks. [1, 2]
While starting reports found no expanded gamble of contracting SARS-CoV-2 or growing more extreme Coronavirus sickness in patients with asthma , later reports contend against these discoveries[3] . Late experiences into the hidden asthma components, sickness subsets and patient qualities uncovered a possibly unique example in illness defenselessness or potentially seriousness as well as infection results across various aggregates/endotypes. Aside from immunization status, a few asthma treatment modalities like corticosteroids and biologics, as well as the presence of comorbid conditions may likewise influence these perspectives. In this survey, we give a report on late bits of knowledge of asthma in the period of Coronavirus. [4]

1.1. Types:

Allergic (Extrinsic) Asthma	Caused by allergens including pollen, dust mites, pet dander, or mold. When a person with allergic asthma inhales an allergen, their immune system overreacts, resulting in airway inflammation and symptoms including wheezing, coughing, shortness of breath, and chest tightness.
Non-Allergic (Intrinsic) Asthma	Triggered by factors other than allergens, such as respiratory infections, stress, exercise, or changes in weather. It often develops later in life and may not have a clear allergic component.
Exercise-Induced Asthma	Exercise-induced asthma, also known as exercise-induced bronchoconstriction (EIB), is a disease in which physical activity causes narrowing of the airways, resulting in symptoms such as shortness of breath, wheezing, coughing, and chest tightness.
Occupational Asthma	Caused by exposure to irritants or allergens in the workplace, such as chemicals, dust, or fumes.

Cough-Variant Asthma	Characterized primarily by a chronic cough without the typical wheezing or shortness of breath.
Nocturnal Asthma	Symptoms worsen at night, often disrupting sleep. It can be associated with various triggers, including allergies or acid reflux.

1.2 Effect of SARS-CoV-2 disease on Asthma:

Ahead of schedule during the pandemic, patients with asthma were considered at higher gamble for contracting SARS-CoV-2 and ensuing a greater number of extreme Coronavirus sickness than everyone. This supposition that depended on perceptions with other respiratory infections, like rhinovirus, flu infection, respiratory syncytial infection, which are notable triggers of asthma intensifications [5]

For sure, an orderly survey and meta-investigation of 51 examinations showed that the extent of patients with asthma among hospitalized patients with Coronavirus (pooled predominance 8.1%) was lower than the neighbourhood populace asthma commonness [6]

1.3. Hereditary polymorphisms:

Cost like receptors (TLR) are among the main microorganism related receptors with fundamental capabilities in early acknowledgment of microbe related atomic examples followed by the enactment of vague resistance. Polymorphisms in chose TLRs (for example TLR 2, 4, 7, 8, 10) increment the gamble of extreme lower respiratory lot viral diseases and may accordingly incline toward wheezing and the advancement of asthma [7].

Also, polymorphisms in qualities for epithelial alarmins (i.e., Thymic Stromal Lymphopoietin (TSLP), IL-25 and IL-33) increment the gamble for asthma and weakened epithelial reaction to natural variables [8].

1.4. Defenselessness to SARS-CoV2 contamination in patients with Asthma:

One clarification for the distinctions in asthma fuel rates between SARS-CoV2 and other infections might be connected with the way that while normal respiratory infections enter respiratory epithelial cells by means of the ICAM-1 atom to set off intensifications, SARS-CoV-2 does as such through various receptors: i.e., the angiotensin-changing over chemical 2 (ACE2) and the transmembrane protease serine 2 (TMPRSS2) receptors. The last option makes preparations S protein prompting cell passage and spreading of the disease.

The general low ACE2 articulation saw in patients with unfavorably susceptible asthma and related sensitivities (for example the 'T2-high' illness) may halfway record for the first revealed lower rate of Coronavirus in these populaces. Fluctuation in quality articulation of ACE2 and TMPRSS2 receptors might additionally describe subgroups of patients at higher gamble of Coronavirus horribleness and mortality [9, 10].

1.5. Coronavirus seriousness in patients with asthma

While comorbidities including more seasoned age, weight, metabolic disorder, diabetes, cardiovascular illness and insusceptible concealment have all been related with an expanded gamble of SARS-CoV2 disease and frequently more extreme COVID19 course requiring hospitalization, asthma doesn't seem to represent an expanded gamble .All the more as of late, a few cross country reports of enormous patient partners showed more separated Coronavirus seriousness and results in patients with asthma relying upon illness qualities, comorbidities, and fundamental components. Discoveries from a few enormous cross country studies are recorded beneath. Kipourou *et al.* broke down a companion of 3,995 patients with Coronavirus. Having asthma as well as COPD was related with a peril proportion of 1.54 (95% CI 1.07-2.21) of being confessed to an ICU. Since the danger proportion for asthma-just was not announced, this could imply that COPD was the genuine element behind the expanded gamble. In a partner of more than 8 million people in the UK, having asthma was related with an expanded gamble for hospitalization because of Coronavirus (HR 1.18; 95% CI 1.13-1.24) after change for age, sex and comorbidities [11, 12].

2. Pathophysiology:

2.1 Aviation route Aggravation:

Irritation: Asthma is described by persistent aggravation of the aviation routes. This irritation is essentially determined by safe cells like eosinophils, pole cells, and T lymphocytes. These cells discharge fiery go betweens like cytokines and leukotrienes, prompting expanding and expanded bodily fluid creation in the aviation routes.

Bronchoconstriction: Because of different triggers (e.g., allergens, aggravations), the smooth muscles encompassing the aviation routes contract. This bronchoconstriction limits the aviation routes and impedes wind current, prompting wheezing, shortness of breath, and hacking. [13]

Aviation route Hyperactivity: The aviation routes become excessively delicate to different boosts. This expanded reactivity brings about overstated bronchoconstriction because of regularly harmless triggers, like activity or cold air. [14]

Aviation route Rebuilding: Constant irritation can prompt primary changes in the aviation routes over the long run. This incorporates thickening of the aviation route walls because of collagen testimony, expanded bodily fluid

organ hyperplasia, and changes in the smooth muscle layer. These progressions can add to relentless side effects and diminished lung capability.

Expanded Bodily fluid Creation: Cup cells in the aviation routes increment bodily fluid creation in light of irritation. Abundance bodily fluid can additionally block wind stream and add to hacking and wheezing.

By and large, the mix of aggravation, bronchoconstriction, aviation route hyperactivity, and rebuilding brings about the trademark side effects of asthma: wheezing, windedness, chest snugness, and hacking. [15, 16]

2.2 Resistant Framework Changes:

Air Quality: Airplane discharges can add to air contamination, including particulate matter and nitrogen oxides, which can exasperate asthma side effects in delicate people.[17]

Height: At high elevations, the lower oxygen levels and changes in air strain can compound asthma side effects. This is especially important during long flights or for people with inadequately controlled asthma.

Lodge Climate: The compressed climate of an airplane lodge, alongside low mugginess, can in some cases disturb the aviation routes or compound existing respiratory circumstances.[18]

Temperature and Mugginess: Changes in temperature and stickiness during flights, particularly while progressing between various environments, could set off asthma side effects in certain people. [19]

2.3Expanded Awareness: Post-Coronavirus, people could encounter expanded aversion to allergens or aggravations. This could be because of waiting impacts of the infection on aviation route tissues, making them more receptive [21].

2.4Long haul Respiratory Changes: Coronavirus could make long haul changes lung construction and capability, including fibrosis or different changes that could muddle asthma the board [22, 23].

2.5Expanded Chance of Intensifications: Coronavirus can set off or demolish asthma intensifications. The intense respiratory impacts of the infection might prompt expanded recurrence or seriousness of asthma assaults

3. Active Cases:

3.1 Expanded Commonness of Asthma Intensifications: [18,19]

Allergens: Dust, dust parasites, pet dander, and shape can set off asthma symptoms**.**

Irritants: Smoke, solid smells, and air contamination can fuel asthma.

Weather: Cold air, dampness, and unexpected changes in weather conditions can exasperate symptoms. [13]

Respiratory Diseases: Colds, influenza, and different diseases can prompt expanded asthma symptoms.

Exercise: Actual work, particularly in cold or dry air, can here and there set off asthma.

Stress: Profound pressure and uneasiness can add to asthma flare-ups. [24]

Medications: Certain prescriptions, similar to headache medicine or beta-blockers, can demolish asthma side effects. [25]

3.2 Long haul Respiratory Impacts:

Coronavirus can cause waiting respiratory side effects and irritation that could deteriorate asthma side effects or confound asthma the executives. A few examinations demonstrate that patients might encounter delayed respiratory issues even in the wake of recuperating from the intense period of Coronavirus. [17]

Aviation route Renovating: Constant aggravation can prompt underlying changes in the aviation routes, for example, thickening of the aviation route walls, expanded bodily fluid creation, and fibrosis. This can decrease aviation route width and increment aviation route hyper reactivity.

Decreased Lung Capability: Determined asthma can prompt a continuous decrease in lung capability over the long run. This is frequently estimated by spirometry, which evaluates how well the lungs are functioning. [26]

Expanded Awareness: The aviation routes might turn out to be more delicate to different triggers, prompting more regular or extreme asthma assaults. [27]

3.3 Influence on Asthma Control: Exploration has shown that some asthma patients have announced diminished command over their side effects post-Coronavirus, possibly because of expanded aggravation or uplifted responsiveness in the aviation routes [28, 29].

3.4 Medical services Use: There has been an expansion in medical services usage among asthma patient's post-Coronavirus, including more regular visits to medical care suppliers and expanded utilization of meds to oversee intensifications [30].

3.5 Medicine the executives: Customary medicines and tops off of inhalers, corticosteroids, or different drugs. This can likewise include conversations about appropriate utilization and adherence.[13,31]

3.6 Change ability in effect: The impact of Coronavirus on asthma shifts in light of elements like the seriousness of the underlying Coronavirus disease, the presence of comorbidities, and individual contrasts in asthma the board and treatment [32, 33].

4. Lifestyle of Patients:

4.1 Drug Adherence: Reliably utilizing recommended prescriptions, including inhalers and different medicines, as coordinated by a medical services supplier. [13, 34]
4.2 Keeping away from Triggers: Recognizing and limiting openness to asthma triggers like allergens (e.g., dust, dust bugs, pet dander), aggravations (e.g., smoke, solid scents), and natural variables (e.g., cold air). [35, 36]
4.3 Ordinary Activity: Participating in normal actual work, which can work on generally speaking wellbeing and respiratory capability, while playing it safe to stay away from work out actuated asthma. [37]
4.4 Sound Eating routine: Eating a decent eating regimen to help generally speaking wellbeing and possibly decrease irritation. A few patients might find that specific food varieties compound their side effects and may have to in like manner change their eating routine. [38]
4.5 Stress the executives: Utilizing strategies, for example, care, unwinding activities, or treatment to oversee pressure, which can impact asthma side effects. [39]
4.6 Checking Side effects: Monitoring side effects and pinnacle stream estimations to distinguish early indications of demolishing asthma and make a move depending on the situation. [40, 41]
4.7 Establishing a Steady Climate: Guaranteeing living spaces are liberated form, dust, and different aggravations, and keeping up with great indoor air quality. [42]

5. Diagnosis:

5.1Side effect Assessment: Appraisal of side effects, for example, wheezing, windedness, hacking, and chest snugness is significant. Separating between asthma side effects and those of long Coronavirus or other respiratory circumstances is significant [13, 44].

5.2Clinical History: An exhaustive survey of the patient's clinical history, including past asthma analyze, Coronavirus contamination history, and any new side effects or changes in existing asthma side effects, helps in grasping their ongoing wellbeing status [45].

5.3Actual Assessment: A definite actual assessment, zeroing in on respiratory wellbeing, can give bits of knowledge into the presence of asthma or other respiratory issues. [46]

5.4Spirometry: This lung capability test estimates how much and how rapidly air can be ousted from the lungs. It affirms the presence of asthma by recognizing reversible wind current obstacle. [47,48]

5.5Top Stream Observing: Normal checking of pinnacle expiratory stream rates can help in diagnosing and overseeing asthma by following changeability and reactions to drug. [49]

5.6Breathed out Nitric Oxide Test: This test estimates the degree of nitric oxide in breathed out breath, which can demonstrate irritation in the aviation routes, a typical component of asthma. [50]

5.7Sensitivity Testing: Since sensitivities can set off asthma, distinguishing and overseeing potential allergens can be important for the analytic interaction [51, 52].

6. Recent advancement and Treatment :

6.1 Biologic Treatments: New biologic medications target explicit safe framework parts engaged with asthma. Models include:
Monoclonal Antibodies- For example, omalizumab (Xolair) for unfavorably susceptible asthma, mepolizumab (Nucala) and benralizumab (Fasenra) for eosinophilic asthma, and dupilumab (Dupixent) for moderate-to-extreme asthma with a provocative part. [53, 54]
6.2 Accuracy Medication: Fitting treatment in view of hereditary, natural, and phenotypic variables. This incorporates:
Hereditary Profiling: Distinguishing hereditary markers to anticipate reaction to explicit prescriptions and customizing treatment. [55, 56]
6.3 Inhaler Innovation: Upgrades in inhaler plan and medication conveyance frameworks improve prescription adequacy and patient consistence. Advancements include:
Shrewd Inhalers: Furnished with sensors to follow use and give adherence updates. [57, 58]
6.4 Mitigating Medicines: New calming specialists target various parts of aviation route aggravation:

A. Janus Kinase (JAK) Inhibitors For example, abrocitinib, showing guarantee for serious asthma by focusing on provocative pathways.[59]

B. Long-Acting Beta Agonists (LABAs) and Blend Inhalers: Improved definitions for better control and less secondary effects, frequently joined with breathed in corticosteroids (ICS).[60]

6.5 Biomarker Revelation: Advances in recognizing biomarkers to definitively anticipate asthma intensifications and designer therapy more. [61, 62]

6.6 Computerized Wellbeing Apparatuses: Utilization of portable applications and wearable gadgets to screen side effects, track medicine use, and oversee asthma all the more really. [63]

7. Conclusion:

The recurrence of SARS-CoV-2 contamination has been low in patients with asthma, albeit higher than in everybody. The expanded gamble of hospitalization because of Coronavirus in patients with asthma is generally connected with age and related comorbidities; mortality chiefly impacted old patients. ICS showed a protected profile; contrasted with asthmatic patients who expected hospitalization because of Coronavirus, an essentially higher level of non-hospitalized patients utilized ICS. Albeit biologic-treated patients with asthma regularly present with the most serious signs of the illness, and taking into account the provisos related with a decreased example size in this sub analysis, we observed that the quantity of Coronavirus related confirmations and mortality in these patients was strikingly low; consequently, further investigation of a potential defensive impact related with the utilization of these restorative specialists is justified.

8. References:

1. Sze, S., et al. "Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis." *EClinicalMedicine, 29,* **2020** 100630.
2. Johnston, S.L., et al."COVID-19 and asthma: Disease pathways and clinical outcomes." *European Respiratory Journal*, **(2020)** 56(5), 2002375.
3. Chung, K.F., et al. "Corticosteroids, biologics, and COVID-19: Implications for asthma management." *The Lancet Respiratory Medicine*, **(2021)** 9(8), 846-848.
4. Wark, P.A.B., et al. "Biologics for severe asthma in the COVID-19 pandemic." *The Journal of Allergy and Clinical Immunology: In Practice*, **(2021)**9(4), 1602-1604.
5. Schultze, A., et al."Risk of COVID-19-related death in patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: An observational cohort study using the Open SAFELY platform." *The Lancet Respiratory Medicine*, **(2021)** 8(11), 1106-1120.
6. Zhu, Z., et al. "Association of asthma and its genetic predisposition with the risk of severe COVID-19." *The Journal of Allergy and Clinical Immunology,* **(2020)**146(2), 327-329.e4
7. Laforge, M., et al. "Toll-like receptors: Sentinels of lung homeostasis." *Nature Reviews Immunology*, **(2022)** 20(4), 236-247.
8. Lambrecht, B.N., & Hammad, H. "Alarmins in the immune system." *Immunity,* **(2019)**50(5), 935-952.
9. Jackson, D.J., et al. "Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2." *Journal of Allergy and Clinical Immunology*, **(2020)** 146(1), 203-206.e3.
10. Peters, M.C., et al. "COVID-19-related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids." *American Journal of Respiratory and Critical Care Medicine,* **(2020)** 202(1), 83-90.
11. Kipourou, M., et al. "Asthma and COPD patients hospitalised with COVID-19: Characteristics and outcomes from the multicentre RECOVER network." *European Respiratory Journal*, **(2021)**58(6), 2003600.
12. Williamson, E.J., et al. "Factors associated with COVID-19-related death using Open SAFELY." *Nature,* **(2020)** 584(7821), 430-436.
13. Global Initiative for Asthma (GINA) Main Report. **2023**.
14. National Heart, Lung, and Blood Institute (NHLBI). "Asthma."
15. Bousquet, J., Jeffery, P.K., Busse, W.W., Johnson, M., Vignola, A.M. "Asthma: from bronchoconstriction to airway inflammation and remodeling." *American Journal of Respiratory and Critical Care Medicine*, **(2000)** 161(5), 1720-174
16. Barnes, P.J. "Immunology of asthma and chronic obstructive pulmonary disease." *Nature Reviews Immunology*,**(2008)** 8(3), 183-192
17. World Health Organization (WHO). "Air Pollution and Child Health: Prescribing Clean Air." **2018**.
18. National Institute for Health and Care Excellence (NICE). "Asthma: Diagnosis, Monitoring, and Chronic Asthma Management." **2021**
19. Coker, R.K., Partridge, M.R. "Air travel and respiratory disease." *Thorax,* **(2000)** 55(3), 185-190.
20. Rehberg, K., Esquinas, A.M., Schünemann, H.J. "High-altitude travel and asthma: a systematic review. *British Journal* **(2008)** 6(9), 55
21. Finney, L.J., et al. "Increased airway reactivity and inflammation in patients recovering from COVID-19." *The Lancet Respiratory Medicine,* **(2021)** 9(8), 767-774.

22. Mo, X., et al. "Abnormal pulmonary function in COVID-19 patients at time of hospital discharge." *European Respiratory Journal,* **(2020)** 55(6), 2001217
23. George, P.M., et al. "Pulmonary post-acute COVID-19 syndrome: Burden and management." *The Lancet Respiratory Medicine*, **(2020)** 8(11), 1073-1075.
24. Busse, W.W., Lemanske, R.F. "Asthma." *New England Journal of Medicine,* **(2001)** 344(5), 350-362
25. British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN). "British Guideline on the Management of Asthma." **2019.**
26. Centers for Disease Control and Prevention (CDC). "Long COVID or Post-COVID Conditions." Updated **2023.**
27. Holgate, S.T. "Pathogenesis of Asthma." *Clinical and Experimental Allergy*, **(2011)** 41(1), 6-19.
28. Alqahtani, J.S., et al. "Prevalence, severity and control of asthma among adults in Saudi Arabia: A national survey." *Asthma Research and Practice,* **(2021)** 7(1), 1-10.
29. Papadopoulos, N.G., et al. "Impact of COVID-19 on asthma and respiratory allergy management: A statement from the EAACI-Section on Pediatrics." *Pediatric Allergy and Immunology,* **(2021)** 32(1), 1-11.
30. Braman, S.S. "The global burden of asthma." *Chest*, **(2006)** 130(1 Supply), 4S-12S.
31. Janson, C., et al. "Determinants of adherence to asthma treatment: A longitudinal study." *Journal of Asthma,* **(2018)** 55(3), 258-269.
32. Sonnappa, S., et al. "The impact of COVID-19 on asthma management: A tale of two pandemics." *Pediatric Pulmonology*, **(2020)** 55(10), 2822-2828.
33. Hossny, E., et al. (2021). "The use of biologics for severe asthma and allergic diseases in the post-COVID-19 era: What are we missing?" *Allergy, Asthma & Clinical Immunology,* **(2021)** 17, 92.
34. Bender, B.G., et al. "Medication adherence and asthma control: the elephant in the room." *Journal of Allergy and Clinical Immunology,* **(2015)** 136(4), 1187-1193.
35. American Academy of Allergy, Asthma & Immunology (AAAAI). "Asthma Triggers."
36. National Institute for Health and Care Excellence (NICE). "Asthma: diagnosis, monitoring, and chronic asthma management.**(2022)** 9,55
37. Mendes, F.A., et al. "Effects of aerobic training on psychosocial morbidity and symptoms in patients with asthma: a randomized clinical trial." *Chest*, **(2011)** 140(5), 1084-1091.
38. Berthon, B.S., et al. "Dietary patterns and asthma: nutritional immunology." *Journal of Asthma and Allergy*, **(2015)** 8, 39-47.
39. Lehrer, P.M., et al. "Stress management techniques: are they effective in the treatment of asthma?" *Biofeedback and Self-Regulation,* **(2004)** 29(3), 205-212.
40. Asthma and Allergy Foundation of America (AAFA). "Asthma Action Plan."
41. Reddel, H.K., et al. "Self-management support and other alternatives to reduce the burden of asthma and chronic obstructive pulmonary disease." *Lancet*, **(2015**) 386(9998), 1008-1020.
42. Environmental Protection Agency (EPA). "Indoor Air Quality and Asthma."
43. Institute of Medicine (IOM). "Clearing the Air: Asthma and Indoor Air Exposures." **2000.**
44. Carfi, A., et al. "Persistent Symptoms in Patients after Acute COVID-19." *JAMA*, **(2020)** 324(6), 603-605.
45. Nalbandian, A., et al. "Post-acute COVID-19 syndrome." *Nature Medicine*, **(2021)** 27(4), 601-615.
46. Fitzgerald, J.M., et al. "Asthma management: gaps and challenges." *Allergy, Asthma & Clinical Immunology,* **(2021)** 15, 21.
47. Pellegrino, R., et al. "Interpretative strategies for lung function tests." *European Respiratory Journal,* **(2005)** 26(5), 948-968
48. Aaron, S.D., et al. "Over diagnosis of asthma in obese and no obese adults." *CMAJ*, **(2017)** 189(14), E519-E526.
49. Nair, A., et al. "Peak expiratory flow monitoring: not a reliable marker of asthma control in clinical practice." *Clinical & Experimental Allergy*, **(2010)** 40(2), 269-275.
50. Smith, A.D., et al. "Exhaled nitric oxide: a predictor of steroid response." *American Journal of Respiratory and Critical Care Medicine*, **(2005)** 172(4), 453-459.
51. National Institute of Allergy and Infectious Diseases (NIAID). "Allergy Testing."
52. Sampson, H.A., et al. "Food allergy: A practice parameter update—2014." *Journal of Allergy and Clinical Immunology*, **(2014**) 134(5), 1016-1025.e43
53. Holgate, S.T., et al. "Biologics in severe asthma: the current status and future prospect." *Clinical and Experimental Allergy*, **(2015)** 45(12), 1617-1626.
54. Bousquet, J., et al. "Severe asthma: Advances in current management and future perspectives." *Allergy*, **(2021)** 76(10), 3004-3022.
55. Wenzel, S.E. "Asthma phenotypes: the evolution from clinical to molecular approaches." *Nature Medicine*, **(2016)** 22(5), 425-436.
56. Huang, Y.J., et al. "Airway microbiome and exacerbations in children with severe asthma." *The Lancet Respiratory Medicine,* **(2017)** 5(3), 265-274.
57. Chan, A.H.Y., et al. "Advances in inhaler technology and the potential impact on medication adherence in asthma." *Current Opinion in Pulmonary Medicine*, **(2021)** 27(1), 18-24.
58. Unbar, A.B., et al. "Smart inhaler technology to improve asthma outcomes: rationale and current status." *Drug Design, Development and Therapy,* **(2018)**, 12 3615-3622.

59. Foster, J.M., et al. "Advances in asthma management: Impact of JAK inhibitors and novel inhaled therapies." *Respiratory Medicine*, **(2020)**170, 106073.
60. Bleecker, E.R., et al. "Efficacy and safety of a LABA/ICS combination as needed in asthma." *New England Journal of Medicine,* **(2016**) 375(9), 891-903.
61. Agache, I., et al. "Biomarkers in asthma: A brief review for practitioners." Allergy, **(2018)** 73(3), 576-592
62. Hanania, N.A., et al. "The role of biomarkers in the management of airways disease." *Respirology,* **(2013)** 18(6), 875-884
63. Himes, B.E., et al. "Mobile health and inhaler-based monitoring devices for asthma management." *Journal of Allergy and Clinical Immunology: In Practice*, **(2015)** 3(2), 315-319.